Fulcrum Therapeutics, Inc.
HealthcareNASDAQ:FULC · NASDAQ Global Market
-$0.10 today
Vol 1.34M · Avg 1.73M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-21.5%
avg -234.4%
ROIC
-23.8%
avg -201.9%
ROA
-20.4%
avg -93.5%
Analysis
ROA is currently the strongest return metric at -20.4% versus its period average of -93.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Alexander C. Sapir | Chief Executive Officer, President & Director | $1.20M | — | 59 | $650,000.00 | 1.20% |
Alan A. Musso | Chief Financial Officer | $802,215.00 | — | 64 | $170,000.00 | 0.31% |
Curtis G. Oltmans | Chief Legal Officer, Head of External Affairs & Corporate Secretary | $689,500.00 | — | 63 | $170,000.00 | 0.31% |
Gregory Tourangeau | Controller & Principal Accounting Officer | — | — | — | $57,000.00 | 0.11% |
Rudolf Jaenisch | Founder | — | — | — | — | — |
Jeffrey W. Jacobs | Chief Scientific Officer | — | — | 63 | — | — |
Danny Reinberg | Founder | — | — | — | — | — |
Michael R. Green | Founder | — | — | — | — | — |
Kim Hazen | Chief People Officer | — | — | — | — | — |
Tsun-Huei Lee | Founder | — | — | 62 | — | — |
Bradley E. Bernstein | Founder | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
8
$59.09M
Net Sentiment
$59.09M
Net selling
Most Active
Gould Robert J
4 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 8 sells worth $59.09M over the last 12 months. That adds up to net selling of $59.09M. Gould Robert J was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +30.0% (9yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Forward estimates point to Revenue at +30.0% (9yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
RAPT Therapeutics, Inc.
RAPT
$959.26M
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
$852.86M
Omeros Corporation
NASDAQ:OMER
$632.20M
Neurogene Inc.
NASDAQ:NGNE
$459.84M
Ocugen, Inc.
NASDAQ:OCGN
$409.61M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$329.81M
Lineage Cell Therapeutics, Inc.
AMEX:LCTX
$316.61M
Bicycle Therapeutics plc
NASDAQ:BCYC
$281.05M
Compass Therapeutics, Inc.
NASDAQ:CMPX
$280.72M
ADC Therapeutics S.A.
NYSE:ADCT
$133.55M
Who manages FULC?
Fulcrum Therapeutics, Inc. (FULC) lists 11 active executives. The top listed executive is Alexander C. Sapir, Chief Executive Officer, President & Director.
Are FULC insiders buying or selling?
Recent insider activity shows net buying of $29.57M.
Explore More
Continue the stock analysis
Jump to another research area for this company.